Institutional experiences with panitumumab monotherapy in metastatic colorectal cancer (mCRC) patients (pts) intolerant to cetuximab No significant financial relationships to disclose. This is an ASCO ...
A genetics‑guided drug, compound 6, targets CARD9 to subtly calm gut inflammation in Crohn’s disease, pointing to safer, longer‑lasting, precision treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results